Abstract 59P
Background
BC is a heterogeneous disease with variable clinical outcomes among patients with the same clinical and pathological characteristics, treated with similar treatment. Despite significant improvement in the outcomes, many of them acquire resistance to multiple anticancer drugs, leading to recurrence and /or metastasis. It remains an unmet need to identify robust molecular defects and novel biomarkers to adopt individualized treatment decisions in BC. CGP using next generation sequencing (NGS) provides more druggable gene aberrations at “one go” that includes somatic BRCA (sBRCA), homologous recombinant repair pathway alteration (HRR) and tumor agnostic markers like tumor mutation burden (TMB) and microsatellite instability (MSI) burden.
Methods
140 BC cases at HCG cancer centre were profiled using Illumina TruSight Oncology 500 assay on a NextSeq2000 in an IRB-approved study. The findings from NGS data were discussed in the molecular tumor board (MTB) and recommendations were documented for change in clinical management and follow-up.
Results
Clinically relevant variants were detected in 133/140 BC patients (95%) with actionable mutations in >80% cases with direct impact on therapy and constituted of 47% Tier 1 and 41% Tier 2 mutations. CGP revealed a multitude of genomic alterations such as PI3KCA/AKT/PTEN signalling pathway (32%) in HR+Her2- mBC and ESR1 mutation (7%) in HR+ mBC predictive of resistance to anti-Her2 and endocrine therapy respectively. 22 patients (16%) with sBRCA and HRR pathways alteration treated either with platinum / PARP inhibitors post platinum treatment were found to have partial-to-complete pathological response (pCR). 23 BC patients with high TMB (16%) were initiated on immunotherapy as a single drug or in combination with chemotherapy and are on follow up. The mutation spectrum, HRR pathway alterations and high TMB of triple- negative BC (TNBC) cases revealed a distinctive mutational profile with clinical utility in >95% cases.
Conclusions
Recommending CGP tests at a more appropriate time helps in modifying BC treatment protocol, clinical decisions and provides patients with greater benefit from targeted treatments based on their specific gene alterations and resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Personal and Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract